„We are very pleased that the m4 Award and the BioM incubation program have already led to three successful company foundations.“
Dr. Petra Burgstaller, Senior Manager Start-Ups & Funding, BioM
The Bavarian “m4 Award” competition addresses academic research projects with spin-off potentials in the pre-seed phase. Its emphasis is on medical biotechnology. The program was launched in 2011 and has an annual budget of 2.5 million €. Academic research groups from Bavaria can apply for project funding of up to 500,000 € for two years. The purpose is to enhance and validate research results and to achieve a start-up phase. Successful projects receive not only financial but also consulting support from BioM, the relevant technology transfer organizations and other experts.
Scientist teams from universities, university hospitals and other publicly promoted research facilities in Bavaria can apply. The applied project should be defined by topic, time and budget and may not have started yet. Of course, all information exchanged within the scope of the m4 Award is confidentially treated. All application and publication rights remain with the applicants.
For further information on the two-stage procedure, please refer to the current call. Call 2019
Since 2016, the call annually alternates between medical biotechnology (m4 Award, guided by BioM) and health economics or medical technology (Medical Valley Award, guided by Medical Valley EMN).
In the years 2011 to 2017, a total of 20 innovative projects with spin-off potential have been awarded.Award Winners 2017
The first spin-off was performed at the end of 2013, becoming Trianta Immunotherapies GmbH. This spin-off of the Helmholtz-Zentrum München, addressing personalized immunotherapies, was taken over by Martinsried-based Medigene AG and is now decisive for the current market capitalization of the listed company.
2014, MetaHeps GmbH was founded, a spin-off of the LMU Munich. The company has developed an innovative platform technology for the prediction of drug-induced liver injury in individual patients.
Preomics GmbH is a spin-off of the Max Planck Institute of Biochemistry in Martinsried. The company was founded in early 2016 and develops innovative platform technologies forproteomic analyses for clinical applications.
T-CURX was founded in spring 2017. Dr. Michael Hudecek from the University Hospital of Würzburg is working on a new generation of CAR T-cells that have a stronger antitumor effect and at the same time prevent an excessive reaction of the immune system.
Further spin-offs are currently under preparation.